Day One Net Income Over Time
| DAWN Stock | USD 11.50 0.34 3.05% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Day One Performance and Day One Correlation. Will Biotechnology sector continue expanding? Could Day diversify its offerings? Factors like these will boost the valuation of Day One. Projected growth potential of Day fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Day One data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.52) | Revenue Per Share | Quarterly Revenue Growth (0.58) | Return On Assets | Return On Equity |
Investors evaluate Day One Biopharmaceu using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Day One's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Day One's market price to deviate significantly from intrinsic value.
It's important to distinguish between Day One's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Day One should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Day One's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Day One Biopharmaceu and related stocks such as Geron, Valneva SE ADR, and Arvinas Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GERN | (10.7 M) | (96.9 M) | (68.9 M) | (38.4 M) | (35.7 M) | 46 K | (29.5 M) | (27.9 M) | (27 M) | (63.6 M) | (75.6 M) | (116.1 M) | (141.9 M) | (184.1 M) | (174.6 M) | (157.1 M) | (149.3 M) |
| VALN | (1.2 M) | (4.4 M) | (14.8 M) | (24.1 M) | (26.3 M) | (20.6 M) | (49.2 M) | (11.5 M) | 3.3 M | (1.7 M) | (64.4 M) | (73.4 M) | (143.3 M) | (101.4 M) | (12.2 M) | (11 M) | (11.6 M) |
| ARVN | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (24 M) | (41.5 M) | (62.1 M) | (111.8 M) | (183.2 M) | (271.9 M) | (367.3 M) | (198.9 M) | (179 M) | (188 M) |
| REPL | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (19.7 M) | (30.8 M) | (52.6 M) | (80.9 M) | (118 M) | (174.3 M) | (215.8 M) | (247.3 M) | (222.6 M) | (211.4 M) |
| TYRA | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (9.3 M) | (26.1 M) | (51.7 M) | (69.1 M) | (86.5 M) | (77.8 M) | (73.9 M) |
| RZLT | (49.3 K) | (49.3 K) | (6.7 M) | (9.7 M) | (11.4 M) | (14.9 M) | (20.3 M) | (29.9 M) | (30.4 M) | (20.3 M) | (20.9 M) | (41.1 M) | (51.8 M) | (68.5 M) | (74.4 M) | (67 M) | (63.6 M) |
| AVBP | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (51.6 M) | (36.9 M) | (69.3 M) | (80.5 M) | (80.5 M) | (72.4 M) | (76.1 M) |
| ATXS | (15.7 K) | (15.7 K) | (15.7 K) | (18.1 M) | (21.9 M) | (32.6 M) | (36.1 M) | (27.4 M) | (25.9 M) | (26.3 M) | (37.1 M) | (194.9 M) | (50.2 M) | (72.9 M) | (94.3 M) | (84.8 M) | (80.6 M) |
| ERAS | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (101.7 M) | (122.8 M) | (242.8 M) | (125 M) | (161.7 M) | (145.5 M) | (152.8 M) |
| VIR | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (69.9 M) | (115.9 M) | (174.7 M) | (298.7 M) | 528.6 M | 515.8 M | (615.1 M) | (522 M) | (469.8 M) | (446.3 M) |
Day One Biopharmaceu and related stocks such as Geron, Valneva SE ADR, and Arvinas Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Day One Biopharmaceu financial statement analysis. It represents the amount of money remaining after all of Day One Biopharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Day One Biopharmaceuticals | DAWN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1800 Sierra Point |
| Exchange | NASDAQ Exchange |
USD 11.5
Check out Day One Performance and Day One Correlation. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Day One technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.